Leveraging Molecular and Immune-Based Therapies in Leptomeningeal Metastases
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1934
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Leveraging Molecular and Immune-Based Therapies in Leptomeningeal Metastases ; volume:37 ; number:1 ; day:6 ; month:12 ; year:2022 ; pages:45-67 ; date:1.2023
CNS drugs ; 37, Heft 1 (6.12.2022), 45-67, 1.2023
- Urheber
-
Wilcox, Jessica A.
Boire, Adrienne A.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40263-022-00975-5
- URN
-
urn:nbn:de:101:1-2023031721104365683938
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:44 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Wilcox, Jessica A.
- Boire, Adrienne A.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Leptomeningeal metastases from solid tumours
Leptomeningeal Metastases: New Opportunities in the Modern Era
Locoregional therapies combined with immune checkpoint inhibitors for liver metastases
Diffuse cerebellar hypermetabolism: an early sign of leptomeningeal metastases
Ventriculoperitoneal shunts equipped with on-off valves for intraventricular therapies in patients with communicating hydrocephalus due to leptomeningeal metastases
Findings to Leptomeningeal Metastases in Lung Cancer: A Case Report
Melanoma Brain Metastases: Local Therapies, Targeted Therapies, Immune Checkpoint Inhibitors and Their Combinations—Chances and Challenges
Targeted Therapies for Melanoma Brain Metastases
Anti-angiogenic therapies in brain metastases
A new approach for leptomeningeal metastases: chemotherapy administered through lumbar intrathecal port
Characteristics and outcomes of non-Hodgkin’s lymphoma patients with leptomeningeal metastases
Leptomeningeal metastasis from hepatocellular carcinoma with other unusual metastases: a case report
Leptomeningeal metastases from solid tumours
Leptomeningeal Metastases: New Opportunities in the Modern Era
Locoregional therapies combined with immune checkpoint inhibitors for liver metastases
Diffuse cerebellar hypermetabolism: an early sign of leptomeningeal metastases
Ventriculoperitoneal shunts equipped with on-off valves for intraventricular therapies in patients with communicating hydrocephalus due to leptomeningeal metastases
Findings to Leptomeningeal Metastases in Lung Cancer: A Case Report
Melanoma Brain Metastases: Local Therapies, Targeted Therapies, Immune Checkpoint Inhibitors and Their Combinations—Chances and Challenges
Targeted Therapies for Melanoma Brain Metastases
Anti-angiogenic therapies in brain metastases
A new approach for leptomeningeal metastases: chemotherapy administered through lumbar intrathecal port
Characteristics and outcomes of non-Hodgkin’s lymphoma patients with leptomeningeal metastases
Leptomeningeal metastasis from hepatocellular carcinoma with other unusual metastases: a case report
Leptomeningeal metastases from solid tumours
Leptomeningeal Metastases: New Opportunities in the Modern Era
Locoregional therapies combined with immune checkpoint inhibitors for liver metastases
Diffuse cerebellar hypermetabolism: an early sign of leptomeningeal metastases
Ventriculoperitoneal shunts equipped with on-off valves for intraventricular therapies in patients with communicating hydrocephalus due to leptomeningeal metastases
Findings to Leptomeningeal Metastases in Lung Cancer: A Case Report
Melanoma Brain Metastases: Local Therapies, Targeted Therapies, Immune Checkpoint Inhibitors and Their Combinations—Chances and Challenges
Targeted Therapies for Melanoma Brain Metastases
Anti-angiogenic therapies in brain metastases
A new approach for leptomeningeal metastases: chemotherapy administered through lumbar intrathecal port
Characteristics and outcomes of non-Hodgkin’s lymphoma patients with leptomeningeal metastases